The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Couldn’t agree more. Moaners should sell up and move on.
Obesity is a huge problem, and it is becoming a bigger problem in more rural communities and in lower socioeconomic groups.
https://www.thelancet.com/journals/lansea/article/PIIS2772-3682(23)00068-9/fulltext#:~:text=As%20per%20the%20NFHS%2D5,abdominally%20obese%20in%20the%20country.
Is there a trading update this week? I have 8th in my diary. I suspect any big news will be combined with TO?
Agreed. Hoping the company report progress about the partnerships and expected regulatory approvals in March.
I think revenues will hit 42-45 million in 2024 with our maturing partnerships. Interested to hear other predictions.
I think last nights RNS told us what’s coming today!
Revenue FY 31 million, net income breakeven. And they may update on distribution deals.
I’ve been reading recently about decellularised tissue scaffolds in regenerative medicine. Think tissue regenix is on the right path, particularly as the elderly population grows.
Probably need to get out more 😜
https://www.nature.com/articles/s41536-023-00312-4
https://www.nature.com/articles/srep13079
There’s too much negativity! Contract wins at 365 million, record revenue, Gen 3, potential for lots more RFQ and likely contracts, internal investment, magna, regulatory requirements.
What on earth is not to like (except share price)…!
Give it time!
Time for more positivity!!
Conclusions:
In conclusion, of the 27 clinical trials of decellularized tissue in orthopaedics identified by a comprehensive survey, nine were completed. Despite the demand for decellularized tissue, not many decellularized tissue products are commercially available now, particularly for the knee joint. However, the variety of available decellularized products, including OrthoPure XT for knee surgery, has recently increased. Therefore, decellularized grafts may become a promising option in orthopaedic surgery.
Does anyone know how the regulatory submission is progressing with Kingsung medical?
Looks like we’ll have to wait another 6 months for the big spike in revenue. No debt, good products, multiple partners in diverse regions. Just need to be patient. Time for a coffee.
I have ProBiotix units. Can you cash them in? What is the unit price? I’m confused 😕 so any advice is appreciated
Thanks 🙏
You do the trial and assess the impact on clinical outcomes in the experimental vs. placebo groups. It might not be blacklisted for long if patients on prebiotics spend one day less in ICU and get discharged earlier.
You do the trial and assess the impact on clinical outcomes
in the experimental vs. placebo groups. It might not be blacklisted for long if patients on prebiotics spend one day less in ICU and get discharged earlier.
Wait until all the regulatory approvals have been achieved for all the disclosed partners and they start producing revenue. I suspect that will be H1 2024. Just bought 7 more shares 😂
What is a realistic market cap of this company? It seems quite low based on paste revenue (not prospective revenue), solid management etc. struggling to find anything negative. #patience is a virtue!!!